Clear.bio raises €1.7 million to accelerate Dutch rollout and secure permanent reimbursement in France and Germany

Clear.bio, the Dutch healthtech pioneer in personalized diabetes care, has successfully closed a €1.7 million funding round this summer. The investment was provided by among others Horizon Flevoland, Future Food Fund, the Dutch Trade & Investment Fund of Invest International and several business angels. With this funding, Clear.bio will accelerate the nationwide rollout of its digital diabetes program in the Netherlands, and obtain permanent reimbursement for its digital therapy in France and Germany.

The Clear.bio app is CE-marked and offers users real-time insights into their glucose data, combined with tailored nutritional advice. By leveraging advanced technology, Clear.bio enables people to effectively manage their health and optimize diabetes control. “This investment allows us to empower more individuals to take charge of their health and expand our proven solution internationally,” says founder Piet Hein van Dam (PhD).”“There are 70 million patients in Europe, all of whom deserve a chance to get rid of this disease without medication.”

Diabetes type 2 continues to rise across Europe. Effective medication is around, but expensive and merely treating the disease instead of curing it. Clear.bio collaborates with healthcare professionals, investors, academic institutions and insurers to make personalized care widely accessible.

Source: Clear.bio